SCHEDULE: RTW Investments Boosts Orchestra BioMed Stake

RTW Investments and its affiliated funds increased their beneficial ownership in Orchestra BioMed Holdings, Inc. to 15.4% through the purchase of pre-funded warrants in a public offering.

Summary

• RTW Investments, LP and its affiliated funds (RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Fund) acquired 3,636,363 pre-funded warrants of Orchestra BioMed Holdings, Inc. on August 4, 2025.
• The warrants were purchased at $2.7499 per warrant, totaling an aggregate purchase price of $9,999,634.61, funded by the working capital of the RTW Funds.
• Following this acquisition, RTW Investments, LP and Roderick Wong, M.D. beneficially own 8,306,063 shares, representing 15.4% of Orchestra BioMed's common stock, based on 53,952,798 outstanding shares as of August 4, 2025.
• The pre-funded warrants have an exercise price of $0.0001 per share, are immediately exercisable, and do not expire.
• Exercise of the warrants is limited such that the RTW Funds cannot own more than 9.99% of the outstanding common stock immediately after exercise, though this limit can be increased to 19.99% with a 61-day notice period.
• Due to the exercise limitations, the shares underlying the pre-funded warrants are not currently considered beneficially owned by the Reporting Persons for Section 13(d) purposes.

Sentiment

Score: 7

Explanation: The filing indicates a significant investment by a major institutional investor, RTW Investments, in Orchestra BioMed, suggesting confidence in the company. While there are limitations on immediate warrant exercise, the overall sentiment is positive due to the substantial capital commitment.

Positives

• Significant investment by RTW Investments, a notable financial entity, indicating confidence in Orchestra BioMed.
• The purchase of pre-funded warrants provides a long-term, flexible investment vehicle with a very low exercise price.

Negatives

• The exercise limitation on the pre-funded warrants (9.99% immediate ownership cap, 61-day delay for increasing the cap) restricts immediate full conversion and beneficial ownership recognition under Section 13(d).

Risks

• Regulatory limitations on warrant exercise: The 9.99% ownership cap and the 61-day waiting period for increasing this cap to 19.99% could limit the RTW Funds' ability to fully convert their warrants into common stock quickly, potentially impacting liquidity or strategic flexibility.
• Dilution risk from future warrant exercises: While not immediately exercisable beyond the cap, the existence of these warrants means potential future dilution when they are eventually exercised.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance from the company itself, but the acquisition of pre-funded warrants by RTW Investments suggests a long-term investment perspective.

Industry Context

This filing indicates continued institutional investor interest in the biomedical sector, specifically in companies like Orchestra BioMed. The use of pre-funded warrants in a public offering is a common mechanism for companies to raise capital and for investors to acquire significant stakes while managing ownership thresholds.

Comparison to Industry Standards

• The acquisition of a 15.4% stake by an institutional investor like RTW Investments is a substantial position, often signaling strong conviction in the company's prospects, comparable to significant investments seen in other emerging biotech or med-tech firms.
• The use of pre-funded warrants with a nominal exercise price and a cap on immediate exercise is a standard structure in public offerings designed to manage immediate dilution and regulatory ownership thresholds for large investors.

Stakeholder Impact

• Shareholders: The significant investment by RTW Investments could be viewed positively, potentially signaling institutional confidence and stability. The public offering itself would have caused some dilution.
• Company (Orchestra BioMed): The capital raised through the public offering, including the sale of warrants to RTW Funds, provides additional funding for the company's operations and strategic initiatives.

Next Steps

• RTW Funds may provide written notice to Orchestra BioMed to increase or decrease their maximum percentage for warrant exercise, up to 19.99%.

Key Dates

Recommendation

The filing details a significant institutional investment by RTW Investments, which is a positive signal of confidence in Orchestra BioMed. However, it is a disclosure of ownership change and a capital raise, not a performance report. While the investment is a good sign, without further financial or operational updates from Orchestra BioMed, a 'hold' recommendation is appropriate for existing investors. New investors might consider this a positive indicator for further due diligence.

Keywords

Orchestra BioMed Holdings, RTW Investments, Schedule 13D, Beneficial Ownership, Pre-Funded Warrants, Public Offering, Biomedical, Healthcare Investment, SEC Filing, Institutional Investor